Picotamide inhibition of excess in vitro thromboxane B2 release by colorectal mucosa in inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 10, Issue 3, 1996, Pages 315-320

  Collins, C E ^a   Benson, M J ^a   Burnham, W R ^b   Rampton, D S ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

^b OLDCHURCH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PICOTAMIDE; THROMBOXANE B2;

ADULT; AGED; ARTICLE; BIOPSY; CLINICAL ARTICLE; COLON MUCOSA; CROHN DISEASE; ENTERITIS; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; PRIORITY JOURNAL; RECTUM MUCOSA; ULCERATIVE COLITIS;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; COLON; CROHN DISEASE; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MALE; MIDDLE AGED; PHTHALIC ACIDS; RECTUM; THROMBOXANE B2;

EID: 0029885179     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0953-0673.1996.00315.x     Document Type: Article

References (33)

1. Lauritsen K, Laursen LS, Bukhave K, Rask-Madsen J. In vivo profiles of eicosanoids in ulcerative colitis, Crohn's colitis and Clostridium difficile colitis. Gastroenterology 1988; 95: 11-7.
2. 2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulphasalazine. Gastroenterology 1981; 81: 444-9.
3. Hawkey CJ, Karmeli F, Rachmilewitz D, Imbalance of prostacyclin and thromboxane synthesis in Crohn's disease. Gut 1983; 24: 881-5.
4. Zifroni A, Treves AJ, Sachar DB, Rachmilewitz D. Prostanoid synthesis by cultured intestinal epithelial and mononuclear cells in inflammatory bowel disease. Gut 1983; 24: 659-64.
5. Rachmilewitz D, Ligumsky M, Haimowitz A, Treves AJ. Prostanoid synthesis by cultured peripheral blood mono-nuclear cells in inflammatory diseases of the bowel. Gastroenterology 1982; 82: 673-9.
6. Rampton DS, Collins CE. Thromboxanes in inflammatory bowel disease: pathogenic and therapeutic implications. Aliment Pharmacol Ther 1993; 7: 357-67.
7. Kitchen EA, Boot JR, Dawson W. Chemotactic activity of thromboxane B2, prostaglandin and their other metabolites for polymorphonuclear leucocytes. Prostaglandins 1978; 16: 3239-44.
8. Paterson IS, Klausner JM, Goldman G, et al. Thromboxane mediates the ischemia-induced neutrophil oxidative burst. Surger 1989; 106: 224-9.
9. Wiles ME, Welbourn R, Goldman G, Hechtman HB, Shepro D. Thromboxane-induced neutrophil adhesion to microvascular and aortic endothelium is regulated by CD18. Inflammation 1991; 15: 181-99.
10. Goldman G, Welbourn R, Klausner JM, et al. Thromboxane mediates diapedesis after ischemia by activation of neutrophil adhesion receptors interacting with basally expressed intercellular adhesion molecule - 1. Circ Res 1991; 68: 1013-9.
11. Goldman G, Welbourn R, Valeri CR, Shepro D, Hechtman HB. Thromboxane A2 induces leukotriene B4 synthesis that in turn mediates neutrophil diapedesis via CD18 activation. Microvasc Res 1991; 41: 367-75.
12. 2 induces ulceration of gastric mucosa. Nature 1981; 292: 472-4.
13. Smith PL, McCafferty GP, Fondacaro JD, et al. Effects of putative thromboxane receptor agonists and antagonists on rat small intestinal ion transport. J Pharmacol Exp Ther 1988; 247: 143-9.
14. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandins endoperoxides. Proc Natl Acad Sci USA 1975; 72: 2994-8.
15. Grainger DN, Rutili G, McCord JM. Superoxide radicals in feline intestinal ischemia. Gastroenterology 1981; 82: 22-9.
16. Wakefield AJ, Sawyerr AM, Dhillon AP, et al. Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction. Lancet 1989; ii: 1057-62.
17. Vilaseca J, Salas A, Guarner F, Rodriguez R, Malagelada JR. Participation of thromboxane and other eicosanoid synthesis in the course of experimental inflammatory colitis. Gastroenterology 1990; 98: 269-77.
18. 2 biosynthesis in endotoxin-induced intestinal damage in the rat. Prostaglandins 1989; 38: 319-33.
19. Hawkey CJ, Boughton-Smith, Whittle BJ. Modulation of arachidonic acid metabolism by sulfasalazine. Dig Dis Sci 1985; 30: 1161-5.
20. Stenson WF, Lobos E. Inhibition of platelet thromboxane synthetase by sulphasalazine. Biochem Pharmacol 1993; 32: 2205-9.
21. Greenfield SM, Punchard NA, Teare JP, Thompson RP. Review article: the mode of action of the aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther 1993; 7: 369-83.
22. Balsano F, Violi F and the ADEP Group. Effect of picotamide on the clinical progression of peripheral vascular disease; a double-blind placebo-controlled study. Circulation 1993; 87: 1563-9.
23. Peskar BM, Dreyling KW, Pesker BA, May B, Goebell H. Enhanced synthesis of sulfido-leucotrienes in UC and Crohn's disease: inhibition by sulphasalazine and 5-aminosalicylates. Agents Actions 1986; 18: 453-60.
24. Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal changes in proctocolitis. BMJ 1964; 1: 89-92.
25. 4 release by rectal mucosa in active UC. Aliment Pharmacol Ther 1992; 6: 163-8.
26. Higgs GA, Moncada S, Salmon JA, Seager K. The source of thromboxane and prostaglandins in experimental inflammation. Br J Pharmacol 1983; 79: 863-8.
27. Stevens TRJ, James J, Simmonds NJ, et al. Circulating von Willebrand factor in inflammatory bowel disease. Gut 1992; 33: 502-6.
28. Webberley MJ, Hart MT, Melikian V. Thromboembolism in inflammatory bowel disease: role of platelets. Gut 1993; 34: 247-51.
29. Collins CE, Cahill MR, Newland AC, Rampton DS. Platelets circulate in an activated state in inflammatory bowel disease. Gastroenterology 1994; 106: 840-5.
30. Doukas J, Hechtman HB, Shepko D. Endothelial secreted arachidonic acid metabolites modulate leukoocyte chemotaxis and diapedesis. Blood 1988; 71: 771-9.
31. Gresele P, Deckmyn H, Nenci GG, Vermylen J. Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders. Trends Pharmacol Sci 1991; 12: 158-63.
32. Casellas F, Papo M, Guarner F, et al. Effects of thromboxane synthase inhibition on in vivo release of inflammatory mediators in chronic ulcerative colitis. Eur J Gastroenterol Hepatol 1995; 7: 221-6.
33. Collins CE, Forbes A, Rampton DS. Antiplatelet therapy in active Crohn's disease: an open trial using picotamide, a thromboxane antagonist. Gastroenterology 1995; 108: A799.